Insulet (PODD) Other Non-Current Assets (2010 - 2026)
Insulet (PODD) reported Other Non-Current Assets of $280.6 million for Q1 2026, down 12.01% on a YoY basis from $318.9 million in Q1 2025, and down 2.64% quarter-over-quarter from $288.2 million in Q4 2025.
Insulet (PODD) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Insulet has reported Other Non-Current Assets for 17 years, with the latest figure at $280.6 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 12.01% year-over-year to $280.6 million; the trailing twelve-month figure through Mar 2026 stood at $280.6 million (down 12.01% YoY), and the FY2025 full-year result was $288.2 million, up 58.79% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $280.6 million, down from $288.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $318.9 million in Q1 2025, with the low at $141.0 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $211.1 million across 5 years, with a median of $188.3 million in 2025.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 97.93% — and 2024, when it dropped 22.68%.
- Insulet's Other Non-Current Assets stood at $210.0 million in 2022, then slipped by 10.38% to $188.2 million in 2023, then fell by 3.56% to $181.5 million in 2024, then surged by 58.79% to $288.2 million in 2025, then dropped by 2.64% to $280.6 million in 2026.
- The last three Other Non-Current Assets figures came in at $280.6 million (Q1 2026), $288.2 million (Q4 2025), and $188.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | - |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 4.04 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 828.89 Mn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 285.90 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 211.40 Mn |
| 10 | Insulet | 10.20 Bn | 9.72 Bn | 529.10 Mn | 280.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 280.60 Mn |
| Dec 31, 2025 | 288.20 Mn |
| Sep 30, 2025 | 188.30 Mn |
| Jun 30, 2025 | 315.10 Mn |
| Mar 31, 2025 | 318.90 Mn |
| Dec 31, 2024 | 181.50 Mn |
| Sep 30, 2024 | 165.90 Mn |
| Jun 30, 2024 | 163.60 Mn |
| Mar 31, 2024 | 187.70 Mn |
| Dec 31, 2023 | 188.20 Mn |
| Sep 30, 2023 | 196.20 Mn |
| Jun 30, 2023 | 211.60 Mn |
| Mar 31, 2023 | 210.60 Mn |
| Dec 31, 2022 | 210.00 Mn |
| Sep 30, 2022 | 178.70 Mn |
| Jun 30, 2022 | 161.90 Mn |
| Mar 31, 2022 | 141.00 Mn |
| Dec 31, 2021 | 106.10 Mn |
| Sep 30, 2021 | 99.60 Mn |
| Jun 30, 2021 | 92.00 Mn |